Updates in HER2 (ERBB2)-Mutant Metastatic Non-small Cell Lung Cancer Treatment:Small Population, Big Unmet Need

Small Population, Big Unmet NeedThe FDA has now approved zongertinib, a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.*For U.S. Healthcare Professionals, please see full Prescribing Information.